Nexpoint Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,495,770
| Closed | -$5.52M | – | 113 |
|
|
2023
Q2 | $5.52M | Hold |
2,495,770
| – | – | 0.8% | 24 |
|
|
2023
Q1 | $6.34M | Buy |
2,495,770
+2,381,000
| +2,075% | +$4.7M | 0.69% | 30 |
|
|
2022
Q4 | $215K | Hold |
114,770
| – | – | 0.02% | 99 |
|
|
2022
Q3 | $295K | Hold |
114,770
| – | – | 0.02% | 113 |
|
|
2022
Q2 | $222K | Hold |
114,770
| – | – | 0.02% | 119 |
|
|
2022
Q1 | $341K | Hold |
114,770
| – | – | 0.04% | 114 |
|
|
2021
Q4 | $516K | Sell |
114,770
-150,000
| -57% | -$712K | 0.07% | 127 |
|
|
2021
Q3 | $1.29M | Hold |
264,770
| – | – | 0.22% | 59 |
|
|
2021
Q2 | $1.81M | Buy |
264,770
+130,000
| +96% | +$1.05M | 0.39% | 40 |
|
|
2021
Q1 | $951K | Sell |
134,770
-5,250
| -4% | -$37.8K | 0.25% | 61 |
|
|
2020
Q4 | $877K | Hold |
140,020
| – | – | 0.29% | 78 |
|
|
2020
Q3 | $758K | Hold |
140,020
| – | – | 0.17% | 90 |
|
|
2020
Q2 | $731K | Sell |
140,020
-20,850
| -13% | -$92.6K | 0.16% | 88 |
|
|
2020
Q1 | $507K | Sell |
160,870
-805,623
| -83% | -$2.97M | 0.1% | 128 |
|
|
2019
Q4 | $3.9M | Hold |
966,493
| – | – | 0.3% | 40 |
|
|
2019
Q3 | $4.18M | Buy |
+966,493
| New | +$3.86M | 0.26% | 55 |
|
Nexpoint Asset Management's PRTK Position: Q3 2023 in Review
Nexpoint Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 2,495,770 shares — an estimated $5.52M sold.
Nexpoint Asset Management first reported a position in PRTK in Q3 2019 and held it in 16 quarters. The position peaked at $6.34M in Q1 2023. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.
- Nexpoint Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Nexpoint Asset Management sold 2,495,770 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $5.52M.
- Nexpoint Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2019 and held it in 16 quarters.
- Nexpoint Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $6.34M in Q1 2023.
- 0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.
Based on Nexpoint Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.